ArticleBlood2017
T-cell expression of AhR inhibits the maintenance of pT
Open access · bronzeAbstract read
In one paragraph
Article in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- The Role of the Gut Microbiota in Allogeneic Hematopoietic Cell Transplantation.American journal of hematology · 2026Review
- Metabolic remodeling of endometriosis microenvironment: Energy stress and immune evasion.iScience · 2026Review
- Targeting hypoxia-inducible factor 1α in chronic graft-versus-host disease to enhance graft-versus-leukemia responses: implications for nanotherapeutics.Frontiers in immunology · 2025Review
- Free fatty acid receptor-4 regulates T-cell-mediated allogeneic reaction through activating an aryl hydrocarbon receptor pathway.Acta pharmaceutica Sinica. B · 2025Article
- Gut Microbiome-Related Anti-Inflammatory Effects of Aryl Hydrocarbon Receptor Activation on Inflammatory Bowel Disease.International journal of molecular sciences · 2024Review
- Gut microbiota, microbiota-derived metabolites, and graft-versus-host disease.Cancer medicine · 2024Review
- Transcriptional regulation of innate lymphoid cells and T cells by aryl hydrocarbon receptor.Frontiers in immunology · 2023Review
- Dissecting the regulatory network of transcription factors in T cell phenotype/functioning during GVHD and GVT.Frontiers in immunology · 2023Review
- Activation of the aryl hydrocarbon receptor inhibits neuropilin-1 upregulation on IL-2-responding CD4Frontiers in immunology · 2023Article
- The absence of AhR in CD4Clinical epigenetics · 2022Article
- Bifidobacterium species associated with breastfeeding produce aromatic lactic acids in the infant gut.Nature microbiology · 2021Observational
- The effects of myeloablative or non-myeloablative total body irradiations on intestinal tract in mice.Bioscience reports · 2021Article
- Crosstalk Between Intestinal Microbiota Derived Metabolites and Tissues in Allogeneic Hematopoietic Cell Transplantation.Frontiers in immunology · 2021Review
- Taming the Sentinels: Microbiome-Derived Metabolites and Polarization of T Cells.International journal of molecular sciences · 2020Review
- Stress responses, M2 macrophages, and a distinct microbial signature in fatal intestinal acute graft-versus-host disease.JCI insight · 2019Article
- Early Notch Signals Induce a Pathogenic Molecular Signature during Priming of Alloantigen-Specific Conventional CD4Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- Microbiome: An Emerging New Frontier in Graft-Versus-Host Disease.Digestive diseases and sciences · 2019Review
- Review
- The Aryl Hydrocarbon Receptor as an Immune-Modulator of Atmospheric Particulate Matter-Mediated Autoimmunity.Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Trisha A DantDepartment of Microbiology and Immunology.
Kaifeng L LinLineberger Comprehensive Cancer Center, and.
Danny W BruceLineberger Comprehensive Cancer Center, and.
Stephanie A MontgomeryLineberger Comprehensive Cancer Center, and.
Oleg V KolupaevLineberger Comprehensive Cancer Center, and.
Hemamalini BommiasamyLineberger Comprehensive Cancer Center, and.
Lisa M BixbyLineberger Comprehensive Cancer Center, and.
John T WoosleyDepartment of Laboratory Medicine and Pathology, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Karen P McKinnonDepartment of Microbiology and Immunology.
Frank J GonzalezNational Cancer Institute, National Institutes of Health, Bethesda, MD.
Bruce R BlazarUniversity of Minnesota Comprehensive Cancer Center, Minneapolis, MN; and.
Benjamin G VincentLineberger Comprehensive Cancer Center, and.
James M CoghillLineberger Comprehensive Cancer Center, and.
Jonathan S SerodyDepartment of Microbiology and Immunology.ORCID 0000-0003-4568-1092
Segeberger Kliniken · DEUniversity of North Carolina at Chapel Hill · USNational Institutes of Health · USUniversity of Minnesota · US
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5MTrial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Mark J Osborn · 1995 to 2026
$48.2MTransgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI SHARPE, ARLENE H. · 2003 to 2023
$42.5MXenobiotic receptorsZIABC005562 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GONZALEZ, FRANK J · 2009 to 2025
$26.9MProject 3: Humoral Targets and B Cell Biology in Chronic Graft-vs.-Host DiseaseP01CA142106 · NCI · DANA-FARBER CANCER INST · PI CUTLER, COREY S · 2009 to 2019
$17.5MEnhancing Treg Therapeutic Efficacy in GVHDR01HL118979 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, HIPPEN, KELI L · 2014 to 2025
$6.7MT-CELL TARGETING FOR GVHDR01HL056067 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1995 to 2022
$5.4MIn Vivo Prevention of Murine GVHDR37AI034495 · NIAID · UNIVERSITY OF MINNESOTA · PI Bruce R Blazar · 2017 to 2026
$5.4MMechanistic Evaluations of ILC2 Cells for the Treatment/Prevention of GVHDR01HL139730 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SERODY, JONATHAN S. · 2017 to 2020
$2.2MTh1/Th17 Macrophage Interactions in Cutaneous GVHDR01CA166794 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SERODY, JONATHAN S. · 2012 to 2016
$1.5MTargeting CCR7 for the Prevention/Treatment of GvHDR01HL115761 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SERODY, JONATHAN S. · 2012 to 2015
$1.4MNCI NIH HHS P01 CA065493NCI NIH HHS P01 CA142106NCI NIH HHS P30 CA016086NCI NIH HHS R01 CA166794NHLBI NIH HHS R01 HL056067NHLBI NIH HHS R01 HL115761NHLBI NIH HHS R01 HL118979NHLBI NIH HHS R01 HL139730NIAID NIH HHS P01 AI056299NIAID NIH HHS R37 AI034495
Abstract
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that affects the function and development of immune cells. Here, we show that recipient mice receiving AhR
Indexed as
Bone Marrow TransplantationAcute DiseaseAnimalsBasic Helix-Loop-Helix ProteinsCell ProliferationColonGene Expression RegulationGraft vs Host DiseaseHumansLymphocyte ActivationMiceMice, Inbred C57BLMice, KnockoutPurinesReceptors, Aryl HydrocarbonSirolimusAHR protein, humanBasic Helix-Loop-Helix ProteinsPurinesReceptors, Aryl HydrocarbonSirolimusStemRegenin 1
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.